Stock Price Updates, Executive Appointments, Acquisitions, Orphan Drug Designations, and Preclinical Developments - Research

    Stock Price Updates, Executive Appointments, Acquisitions, Orphan Drug
    Designations, and Preclinical Developments - Research Report on Ariad,
                   Halozyme, DepoMed, Omeros, and BioCryst

PR Newswire

NEW YORK, December 23, 2013

NEW YORK, December 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Ariad
Pharmaceuticals Inc. (NASDAQ: ARIA), Halozyme Therapeutics, Inc. (NASDAQ:
HALO), DepoMed Inc. (NASDAQ: DEPO), Omeros Corporation (NASDAQ: OMER), and
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Ariad Pharmaceuticals Inc. Research Report

On December 18, 2013, Ariad Pharmaceuticals Inc.'s (Ariad) stock ended the
day's session at $4.98, which is 19.71% higher than the previous day's closing
price of $4.16. The Company's stock gained 25.13% over the past three trading
days as compared to the Dow Jones Industrial Average Index, which ended 2.62%
higher over the same trading period. The Full Research Report on Ariad
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/161c_ARIA

Halozyme Therapeutics, Inc. Research Report 

On December 17, 2013, Halozyme Therapeutics Inc. (Halozyme) announced
executive appointments. According to the Company, Helen Torley, M.B. Ch. B.,
M.R.C.P., will join Halozyme as President and CEO, effective January 6, 2014.
Halozyme reported that Torley will also become a member of the Board of
Directors. According to Halozyme, Dr. Torley most recently served as Executive
Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, a
subsidiary of Amgen. "Helen's demonstrated leadership of Onyx's oncology
products will build on Halozyme's trajectory of value creation, pivoting from
partnered to proprietary products," said Kenneth J. Kelley, Chairman of the
Board of Directors of Halozyme. The Company stated that Gregory I. Frost,
Ph.D. will be departing Halozyme as he takes on the role as Head of Intrexon's
Health Sector, effective January 6, 2014, however, Dr. Frost will continue to
lead Halozyme's Scientific Advisory Board. The Full Research Report on
Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea1b_HALO

DepoMed Inc. Research Report

On December 17, 2013, DepoMed Inc. (Depomed) announced the acquisition of the
US rights to CAMBIA (diclofenac potassium for oral solution) from Nautilus
Neurosciences (Nautilus) for $48.7 million. According to the Company, Depomed
may pay Nautilus up to an additional $5 million based on the achievement of
certain annual net sales milestones. "CAMBIA, our third product acquisition in
18 months, is a unique and fast acting treatment for migraine with long-term
growth potential that is a great fit in our pain and neurology-focused
portfolio," said Jim Schoeneck, President and CEO of Depomed. "Some of the
capital secured in October 2013 from the sale of our royalties in type 2
diabetes assets is being put to work in this product acquisition that
leverages our current infrastructure. We will continue to actively seek
products that complement our pain and neurology portfolio and position us for
a strong growth trajectory in the coming years." The Full Research Report on
DepoMed Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/edda_DEPO

Omeros Corporation Research Report

On December 18, 2013, Omeros Corp. (Omeros) announced that the US Food and
Drug Administration (FDA) has granted an orphan drug designation to OMS721,
the Company's lead human monoclonal antibody targeting mannan-binding
lectin-associated serine protease-2 (MASP-2) for the prevention of
complement-mediated thrombotic microangiopathies (TMAs). "We are pleased that
the FDA has granted orphan drug designation for OMS721. The designation should
accelerate the development of OMS721 and, given the limitations of current
treatments for TMAs, we look forward to initiating our Phase 2 clinical
program next quarter," said Gregory A. Demopulos, M.D., Chairman and CEO of
Omeros. "The remainder of this year and the first part of 2014 promise to be
exciting times across other Omeros programs as well. This month we will
initiate our OMS824 Phase 2 clinical program in Huntington's disease - earlier
granted orphan drug designation by the FDA - and could also report Phase 2a
data for OMS824 in schizophrenia. We then look to the potential marketing
approval of Omidria, its launch completing our transition to a commercial
company." The Full Research Report on Omeros Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/e3c9_OMER

BioCryst Pharmaceuticals, Inc. Research Report

On December 18, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced the
selection of two optimized plasma kallikrein inhibitors to advance into
preclinical development as potential once-daily, oral treatments for the
prevention of hereditary angioedema (HAE) attacks. According to BioCryst, the
second generation discovery program's goals of improving selectivity and
bioavailability compared to BCX4161 were both met, with no effect on
prothrombin time at high concentrations ( > 50 micromolar), and oral fraction
absorbed exceeding 25%. BioCryst also discovered that compounds demonstrate
sub-nanomolar potency on the isolated enzyme and single digit nanomolar
potency in suppressing kallikrein activity in an ex vivo activated human
plasma kallikrein inhibition (aPKI) assay. "We are pleased with the outcome of
our discovery program for second-generation plasma kallikrein inhibitors,"
said Yarlagadda S. Babu, Ph.D., Senior Vice President, Drug Discovery at
BioCryst. "We look forward to evaluating nonclinical safety in the preclinical
development phase, and to providing updates regarding our progress towards our
goal of developing a once-daily prophylactic therapy for hereditary
angioedema." The Full Research Report on BioCryst Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/f9b1_BCRX

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.